Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

J&J's Simponi Helps Colitis Patients In Clinical Trial

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/21/2012 | 08:45pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (>> Johnson & Johnson) said its drug Simponi improved symptoms in a majority of patients with an inflammatory-bowel disease in a new clinical trial.

The results, released at a medical conference Monday, could support expansion of the approved uses of Simponi to include treating the bowel condition, known as ulcerative colitis, which J&J estimates affects about 700,000 people in the U.S.

Simponi, which was introduced in 2009, is currently approved to treat signs and symptoms of moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.

Simponi is known as an anti-tumor necrosis factor, or anti-TNF, a category that also includes J&J's older drug, Remicade, which is already approved to treat ulcerative colitis. Simponi can be self-administered by patients as an injection, while Remicade requires intravenous infusion by a health-care provider.

J&J recorded $410 million in Simponi sales for 2011; Merck & Co. (MRK), which markets the drug in certain countries outside the U.S., recorded $264 million in Simponi sales for 2011.

J&J tested Simponi in a late-stage clinical trial of more than 770 patients with moderately to severely active ulcerative colitis who had failed to respond to or tolerate certain other treatments.

Some patients received Simponi--at two different dose levels--and some received a placebo, and researchers tracked how many experienced a clinical response at six weeks after the start of treatment. Clinical response included improvements in various symptoms of ulcerative colitis such as diarrhea.

According to J&J, 51.8% and 55% of patients in the two Simponi groups, respectively, achieved a clinical response at week 6, versus 29.7% of placebo patients. The results were presented Monday at the Digestive Disease Week medical meeting in San Diego.

In a secondary measure in the trial, roughly 18.7% and 17.8% of patients in the Simponi groups had clinical remission, versus 6.3% in placebo patients.

The rates of adverse events were comparable among the Simponi and placebo groups, and J&J said the safety of Simponi in the colitis study was consistent with the drug's safety profile in the diseases for which it's already approved.

As a class of drugs, Simponi and other anti-TNFs are associated with increased risk of infections and certain forms of cancer such as lymphoma.

The data suggest Simponi could be a new treatment option for ulcerative colitis patients who don't respond to other drugs, or who prefer the convenience of a subcutaneous injection, said William Sandborn, chief of the division of gastroenterology at the University of California, San Diego, and lead investigator of the J&J-funded study.

J&J also has studied Simponi over a longer treatment duration in colitis patients, and results are expected later this year.

J&J plans to apply for U.S. and European regulatory approval of Simponi as a treatment for ulcerative colitis this year, said J&J spokesman Brian Kenney.

Abbott Laboratories (>> Abbott Laboratories) also has applied for regulatory approval of its anti-inflammatory drug, Humira, as a treatment for ulcerative colitis. European regulators have approved the new indication.

Last year, the FDA declined to approve J&J's requests to market Simponi's ability to inhibit progression of structural damage in both rheumatoid arthritis and psoriatic arthritis.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stocks mentioned in the article : Johnson & Johnson, Abbott Laboratories
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04/25 JOHNSON & JOHNSON : Human Performance Institute Launches Corporate Athlete® Resi..
04/25 ACTELION : Publication of the provisional notice of the end result of Actelion t..
04/25 JOHNSON & JOHNSON : enters `Active Kids` personal care space
04/24 J&J, Takeda among interested in Brazil's Hypermarcas, sources say
04/24 JOHNSON & JOHNSON : to Host Pharmaceutical Business Review
04/24 JOHNSON & JOHNSON : Reports 2017 First-Quarter Results
04/22 JOHNSON & JOHNSON : Sun Sentinel Ira Winderman column
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 The DOs and the DON’Ts of a media pitch
04/20 JOHNSON & JOHNSON : DePuy Synthes Acquires Tissue Regeneration System’s 3D..
More news
Sector news : Pharmaceuticals - NEC
04/25DJSHIRE : Files 8K - Other Events
04/25DJSHIRE : Files 8K - Changes To Articles
04/25DJNasdaq Composite Tops 6000 for First Time
04/25DJASTRAZENECA : Lung Cancer Treatment Approved in EU
04/25DJELI LILLY AND : Working to Cut Costs
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/25 No Thank You, Philip Morris International
04/25 Elroy's Chart Corner
04/25 5 YEARS IN SEEKING ALPHA'S 'DGI FUN : Mistakes Made, Lessons Learned - And Triu..
04/25 Danish Biotech Genmab Designed Johnson & Johnson's Fastest-Growing Drug
04/25 RETIREMENT STRATEGY : Has This Bank Become Perfect For Your Retirement Portfolio..
Advertisement
Financials ($)
Sales 2017 75 714 M
EBIT 2017 23 391 M
Net income 2017 17 887 M
Debt 2017 6 597 M
Yield 2017 2,74%
P/E ratio 2017 18,74
P/E ratio 2018 16,83
EV / Sales 2017 4,49x
EV / Sales 2018 4,31x
Capitalization 333 142 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 129 $
Spread / Average Target 4,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON6.67%333 142
ROCHE HOLDING LTD.8.21%220 797
PFIZER INC.3.88%200 926
NOVARTIS AG-1.08%195 490
MERCK & CO., INC.5.55%170 359
SANOFI10.33%119 103
More Results